Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of Dermatology at the University of California Davis in Sacramento, spoke on the advancement in precision medicine within dermatology and what role genetics, research, and immunology can have for care management going forward.
Watch
Real-world Data Demonstrate Strength, Durability of Checkpoint Inhibitor Use in cSCC
December 10th 2022Response, progression-free survival, overall survival, time-to-next-treatment, and toxicity outcomes were evaluated among patients with advanced cutaneous squamous cell carcinoma (cSCC) who received first-line treatment with immune checkpoint inhibitors.
Read More
I-SPY2 Supports Neoadjuvant Cemiplimab/REGN3767 in Early-Stage, High-Risk Breast Cancer
December 10th 2022The ongoing multicenter open-label adaptively randomized phase 2 I-SPY2 trial is currently investigating dual immune blockade with cemiplimab plus the investigational agent REGN3767 as neoadjuvant therapy for early-stage, high-risk breast cancer, and new data were presented yesterday at the San Antonio Breast Cancer Symposium.
Read More
10-Year Babytam Data Show Reduced-Dose Tamoxifen Still Producing Positive Results
December 9th 2022Babytam is the 5-mg daily dose of tamoxifen being studied in the ongoing TAM-01 study, which is investigating incidence of invasive breast cancer or ductal carcinoma in situ among high-risk women who have received the treatment regimen for 3 years.
Read More
Dr Lola Fayanju Shares How Providers Can Leverage PROs to Improve Breast Cancer Care
December 9th 2022Patient-reported outcomes (PROs) within breast cancer settings can be instrumental in helping patients feel heard and improving their overall quality of care, said Oluwadamilola "Lola" Fayanju, MD, MA, MPHS, FACS, chief of breast surgery at Penn Medicine.
Watch
Two Pediatric Tertiary Care Centers Evaluate Efficacy of CBD on Refractory, Intractable Epilepsy
December 9th 2022Abstracts from the American Epilepsy Society (AES) display potential benefits of cannabidiol (CBD) on pediatric patients with epilepsy in tertiary care centers and highlight areas where further research is needed.
Read More
Childhood Maltreatment Associated With Atopic Disease
December 9th 2022Patients exposed to childhood maltreatment were at greater risk for developing atopic disease compared with unexposed counterparts, and risk of atopic dermatitis and allergic rhinoconjunctivitis may have been attentuated by misdiagnosis.
Read More
Dr William Jacout Offers Advice for Providers Using Genomics to Inform Breast Cancer Treatment
December 9th 2022William Jacout, MD, a medical oncologist and researcher at the Institut du Cancer de Montpellier Val d'Aurelle in France, shares what providers should keep in mind when using genomics as a diagnostic and treatment decision-making tool for patients with breast cancer.
Watch
Dr Douglas Mann on Next Steps to Studying Gene Editing in Heart Failure
December 9th 2022Initial data on NTLA-2001, which is a novel investigative intravenous agent that works to prevent development of cardiac transthyretin (ATTR) amyloidosis by targeting the TTR gene and TTR protein levels, were presented at this year’s American Heart Association’s Scientific Sessions in Chicago.
Watch
Optimizing Screening MRI for Women With High Risk of Breast Cancer
December 9th 2022The utility of annual MRI plus mammogram was investigated in a new meta-analysis delivered at this year’s San Antonio Breast Cancer Symposium, with the goal of optimizing use of MRI by considering potential for overdiagnosis and tailoring to age and risk group.
Read More
Flight Home From Pharmacy Conference Holds More Surprises With Medical Emergency
December 9th 2022As they headed home Thursday from the 2022 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting & Exhibition in Las Vegas, pharmacists pitched in to help a man having a medical emergency aboard a United flight bound for Newark, New Jersey.
Read More
Dr Adam Brufsky Describes the Evolution of Treatment Options for HER2-Low Breast Cancer
December 8th 2022Human epidermal growth factor receptor 2 (HER2)-low breast disease has a number of new treatments available, and more providers need to be aware of how it differs from other forms of breast cancer, according to Adam Brufsky, MD, PhD, University of Pittsburgh, at the San Antonio Breast Cancer Symposium.
Watch
ICYMI: Top Highlights From ACC 2022
December 8th 2022The American College of Cardiology’s 71st Scientific Session covered how to address the impact of social determinants of health on cardiovascular outcomes, understanding the latest developments in digital health, and the role of COVID-19 on heart health.
Read More
New Research Highlights Clinical Significance of HER2-Low Breast Disease
December 8th 2022With human epidermal growth factor receptor 2 (HER2)–low breast cancer still a relatively newly classified disease subtype, research is increasingly focused on the disease, in which cells express lower levels of the HER2 protein than are adequate to classify a patient as having HER2-positive disease.
Read More